N4 Pharma raises £1million through a placing

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that it has raised £1 million (before expenses) through a placing of 50,000,000 new ordinary shares of 0.4p each in the Company at an issue price of 2p per Placing Share.  The Placing was undertaken by Turner Pope Investments (TPI) Limited.

The net proceeds of the Placing will be used to progress the Company’s development work relating to the loading of SiRNA onto Nuvec®, including to commit to doing in-vivo studies and also to explore acquisition opportunities.

Nigel Theobald, Chief Executive of N4 Pharma, commented: “The additional funding raised provides sufficient working capital for our Nuvec® program into 2024 and will enable us to do more in vivo development work on double loaded SiRNA on Nuvec® and begin business development on this opportunity.  Alongside this, we will undertake further research to support our patent application on the use of Nuvec® to improve the efficiency of viral vectors and start business development activities in this area.

“This funding will also give us more scope to continue to look for additional asset opportunities alongside Nuvec.”

Broker Offer

To provide shareholders and other investors who did not initially participate in the Placing the opportunity to invest in the Company, under the Placing Agreement, TPI will launch a broker offer under which TPI will, as agent for the Company, invite subscriptions for additional new ordinary shares with an initial expected value of £0.25 million at the Issue Price.  The Broker Offer may be extended, with the express agreement of the Company, to £1.0 million in the event the Broker Offer is oversubscribed.  The Broker Offer opens immediately following this announcement and will close at 4.30 p.m. on 21 November 2022.

As far as is practical, participation in the Broker Offer will be prioritised for qualifying shareholders (direct or indirect) on the Company’s share register at the close of business on 17 November 2022 (“Existing Shareholders”).  If the maximum subscription under the Broker Offer is taken up, it will raise an additional £1 million, before expenses, for the Company.

To subscribe for Broker Offer Shares, Existing Shareholders or other interested parties who wish to register their interest in participating in the Broker Offer should click on the following link : N4 Pharma Broker Offer

A further announcement will be made following the end of the period during which the Broker Offer is open.  If the Broker Offer is not fully subscribed by 4.30 p.m. on 21 November 2022, orders from eligible investors will be satisfied in full, and the balance of the Broker Offer shall lapse.

Broker Warrants

As part of its fee, TPI will be issued with warrants (“Broker Warrants”) to subscribe for new ordinary shares exercisable at the Issue Price, such number of warrants that would be equivalent to 6 (six) per cent. of the gross aggregate value of funds raised in the Placing and Broker Offer.  The Broker Warrants have a term of 36 months from the date of admission of the Broker Offer Shares to trading on AIM and are being issued under the Company’s existing share authorities.

Application for Admission

The Placing has been conducted utilising the Company’s existing share authorities.  Application has been made for the Placing Shares to be admitted to trading on AIM (“Admission”) and it is expected that Admission will take place at 8.00 a.m. on or around 24 November 2022.  Once issued, the Placing Shares will rank pari passu with the Company’s existing ordinary shares. 

A further announcement will be made regarding the admission to trading of the Broker Offer Shares to be issued pursuant to the Broker Offer which is also being conducted utilising the Company’s existing share authorities.

Total Voting Rights

Following Admission of the Placing shares, the enlarged issued share capital of the Company will comprise 231,080,349 ordinary shares of 0.4 pence each.  The Company does not hold any ordinary shares in treasury.  Consequently, 231,080,349 is the figure which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure and Transparency Rules. A separate notification will be made following closure of the Broker Offer.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    N4 Pharma

    More articles like this

    N4 Pharma

    N4 Pharma Broker Offer to raise a maximum of £1 million

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an opportunity for shareholders and other investors who did not participate in the fundraising announced today to

    N4 Pharma

    N4 Pharma updates on patent filing

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an update on its patent application for Nuvec®, filed in March 2020 (no. PCT/GB2021/050960 Gene Therapy Vectors).

    N4 Pharma

    N4 Pharma successful Nuvec double siRNA testing

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced successful in vitro testing of Nuvec® loaded with two small interfering RNA (siRNA) probes. On 14 September 2022, the Company

    N4 Pharma

    N4 Pharma continue to make excellent progress

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, has announced its unaudited interim results for the six months ended 30 June 2022. Highlights: ·      Exciting opportunities identified for

    N4 Pharma

    N4 Pharma plans for commercialising Nuvec (VIDEO)

    N4 Pharma plc (LON:N4P) CEO Nigel Theobald chats to DirectorsTalk Interviews about its development plans for commercialising Nuvec. Nigel talks us through the update highlights, explains why companies working with siRNA are much more open to using novel delivery

    N4 Pharma

    N4 Pharma’s proof of concept work is extremely encouraging

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced an update on its current work programmes. Highlights: ·      Medicines Discovery Catapult study shows demonstrable suppression of tumour

    N4 Pharma

    N4 Pharma AGM to be held on 24 March 2022

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that the Company’s audited accounts for the year ended 31 December 2021, together with the notice of

    N4 Pharma

    N4 Pharma EPO patent granted for Nuvec

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that further to the Company’s announcement dated 11 February 2021 in which it was stated that the

    N4 Pharma

    N4 Pharma acceleration in understanding of the capabilities of Nuvec

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, has announced its unaudited interim results for the six months ended 30 June 2021. Highlights: ·      Continued strategy to focus on three

    No more posts to show